In patients with diabetic kidney disease, neither ACEi (RR 0.91; 95% CI 0.71-1.17) nor AIIRA (RR 0.99; 95% CI 0.85-1.17) significantly reduced all-cause mortality compared to placebo overall.
Meta-Analysis (n=13,215)
Does ACEi or AIIRA reduce all-cause mortality and improve renal outcomes in patients with diabetic kidney disease?
Full-dose ACE inhibitors, but not AIIRAs or lower-dose ACE inhibitors, significantly reduce all-cause mortality in patients with diabetic kidney disease compared to placebo.
Relative Risk: 0.91 (95% CI 0.71–1.17)
BACKGROUND: Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor antagonists (AIIRA) are considered to be equally effective for patients with diabetic kidney disease (DKD), but renal and not mortality outcomes have usually been considered. OBJECTIVES: To evaluate the benefits and harms ACEi and AIIRA in patients with DKD. SEARCH STRATEGY: We searched MEDLINE (1966 to December 2005), EMBASE (1980 to December 2005), the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library issue 4 2005) and contacted known investigators. SELECTION CRITERIA: Studies comparing ACEi or AIIRA with placebo or each other in patients with DKD were included. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data. Statistical analyses were performed using the random effects model and results expressed as relative risk (RR) with 95% confidence intervals (CI). Heterogeneity among studies was explored using the Cochran Q statistic and the I(2) test, subgroup analyses and random effects metaregression. MAIN RESULTS: Fifty studies (13,215 patients) were identified. Thirty eight compared ACEi with placebo, five compared AIIRA with placebo and seven compared ACEi and AIIRA directly. There was no significant difference in the risk of all-cause mortality for ACEi versus placebo (RR 0.91, 95% CI 0.71 to 1.17) and AIIRA versus placebo (RR 0.99, 95% CI 0.85 to 1.17). A subgroup analysis of studies using full-dose ACEi versus studies using half or less than half the maximum tolerable dose of ACEi showed a significant reduction in the risk of all-cause mortality with the use of full-dose ACEi (RR 0.78, 95% CI 0.61 to 0.98). Baseline mortality rates were similar in the ACEi and AIIRA studies. The effects of ACEi and AIIRA on renal outcomes (ESKD, doubling of creatinine, prevention of progression of micro- to macroalbuminuria, remission of micro- to normoalbuminuria) were similarly beneficial. Reliable estimates of effect of ACEi versus AIIRA could not be obtained from the three studies in which they were compared directly because of their small sample size. AUTHORS' CONCLUSIONS: Although the survival benefits of ACEi are known for patients with DKD, the relative effects on survival of ACEi with AIIRA are unknown due to the lack of adequate direct comparison studies. In placebo controlled studies, only ACEi (at the maximum tolerable dose, but not lower so-called renal doses) were found to significantly reduce the risk of all-cause mortality. Renal and toxicity profiles of these two classes of agents were not significantly different.
Strippoli et al. (2006) conducted a meta-analysis in Diabetic kidney disease (n=13,215). Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor antagonists (AIIRA) vs. Placebo or each other was evaluated on All-cause mortality (ACEi vs placebo) (RR 0.91, 95% CI 0.71 to 1.17). In patients with diabetic kidney disease, neither ACEi (RR 0.91; 95% CI 0.71-1.17) nor AIIRA (RR 0.99; 95% CI 0.85-1.17) significantly reduced all-cause mortality compared to placebo overall.